| Oct 8 |
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?
|
| Sep 18 |
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
|
| Sep 17 |
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
|
| Sep 10 |
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
|
| Aug 10 |
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
| Aug 9 |
Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 7 |
Aclaris Therapeutics GAAP EPS of -$0.15, revenue of $2.8M
|
| Aug 7 |
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 7 |
Aclaris: Q2 Earnings Snapshot
|
| Aug 7 |
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
|
